Crown Therapeutics

Crown Laboratories is a private, commercial-stage dermatology and aesthetics company that, following its acquisition of Revance Therapeutics in February 2025, now operates under the Revance name. The business markets a broad portfolio spanning therapeutic skincare, prestige skincare, aesthetic injectables, dermal fillers, and medical devices. Its key branded assets include DAXXIFY for aesthetics and therapeutics, the Teoxane RHA filler portfolio in the U.S., SkinPen microneedling devices, and consumer/therapeutic skincare brands such as PanOxyl, Blue Lizard, StriVectin, Sarna, and BIOJUVE. The company is focused on skin health and aesthetic medicine rather than a traditional R&D-heavy biotech pipeline, with revenues driven primarily by marketed products and brand commercialization. It also maintains cGMP manufacturing capabilities for topical and semi-solid products in Tennessee.